V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015684 | 160013053 | 1.65 | 89.1 | Palliative (P) | 2014-05-16 | 2017-08-09 | GEMCITABINE | 02 | N | DACARBAZINE | 101515064 |
| 160015689 | 160013054 | 1.64 | 80 | Curative (C) | 2018-09-04 | 2018-12-08 | NB BEACON Temozolomide Topotecan | 01 | N | STS RHABDO RMS 2005 VIN CYCLO | 101092894 |
| 160015693 | 160013055 | 0 | 15.8 | null | 2017-09-18 | 2018-04-06 | IVA | null | null | STS RHABDO RMS 2005 VIN CYCLO | 100430511 |
| 160015696 | 160013056 | 1.84 | 62.1 | Neo-adjuvant (N) | 2020-04-05 | 2020-05-26 | Ifosfamide | null | null | CYCLOPHOSPHAMIDE + VINORELBINE | 100650157 |
| 160015697 | 160013057 | 1.68 | 115.8 | Curative (C) | 2017-11-10 | 2017-11-11 | Ribociclib | 02 | N | EW EUROEWING 2012 ARM A/B ZOL ACID | 101271254 |
| 160015698 | 160013058 | 1.84 | 64.2 | Curative (C) | 2018-07-18 | 2018-08-05 | STS Rhabdo RMS 2005 Vin Cyclo | 01 | N | IPILIMUMAB + NIVOLUMAB | 101424905 |
| 160015699 | 160013059 | 0 | 92.2 | null | 2018-06-08 | 2018-06-25 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | null | NIRAPARIB | 100761742 |
| 160015700 | 160013060 | null | 49 | null | 2018-04-16 | 2018-05-02 | Abiraterone | null | null | EW EUROEWING 2012 ARM B VC | 100400047 |
| 160015704 | 160013062 | 1.75 | 82.4 | Palliative (P) | 2018-07-01 | 2018-07-03 | EW EuroEwing 2012 Arm B VC | 02 | null | NB HRNBL | 100066090 |
| 160015709 | 160013063 | 0 | 69 | Curative (C) | null | 2018-07-17 | Doxorubicin + Ifosfamide | 02 | N | DACARBAZINE + GEMCITABINE | 101579069 |
| 160015710 | 160013064 | 0 | 14.6 | Palliative (P) | 2020-03-23 | 2020-05-05 | null | 02 | N | IFOSFAMIDE | 100023699 |
| 160015712 | 160013065 | 1.2 | 12.3 | null | 2020-09-05 | 2021-03-08 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | null | CISPLATIN + PACLITAXEL | 100083795 |
| 160015721 | 160013066 | 1.63 | 67 | null | 2021-05-08 | 2021-05-22 | Trastuzumab emtansine (Kadcyla) 1st | 02 | null | CONFIRM TRIAL | 101287278 |
| 160015723 | 160013067 | 1.62 | 83 | null | null | 2019-10-14 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100776439 |
| 160015726 | 160013068 | null | 60 | null | 2016-09-10 | 2016-09-23 | NB HRNBL-1 BUMEL MAT | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100531820 |
| 160015727 | 160013069 | 0 | 99.7 | 03 | 2017-05-22 | 2017-06-04 | CARBOPLATIN + VINORELBINE | 02 | N | VENETOCLAX | 100830885 |
| 160015728 | 160013070 | 0.98 | 13.9 | null | 2017-11-04 | 2017-12-16 | Ifosfamide | 02 | null | ENZALUTAMIDE | 101252207 |
| 160015730 | 160013072 | 1.79 | 15.6 | null | 2018-05-07 | 2019-02-19 | Cyclophosphamide PO +Vinorelbine IV | 02 | null | DINUTUXIMAB BETA | 100000895 |
| 160015732 | 160013073 | 1.3 | 78.7 | Curative (C) | 2019-07-13 | 2019-07-13 | NB HRNBL-1 COJEC Ind COURSE B | 02 | N | CISPLATIN + GEMCITABINE | 100872779 |
| 160015739 | 160013074 | 0 | 57.4 | Curative (C) | 2018-01-04 | 2018-05-28 | ETOPOSIDE + IFOSFAMIDE | 02 | N | DARATUMUMAB | 100125940 |
| 160015740 | 160013075 | 1.65 | 62.3 | Neo-adjuvant (N) | 2021-09-06 | 2021-10-28 | EW EuroEwing 2012 Arm A VAI | 02 | N | OLARATUMAB | 100638111 |
| 160015741 | 160013076 | 1.65 | 20 | Curative (C) | 2019-10-19 | 2019-10-19 | Etoposide + Ifosfamide (3 days) | N | N | NB BEACON DINUTUXIMAB + TEMOZOLOMIDE + TOPOTECAN | 101135079 |
| 160015744 | 160013077 | 0 | 81.3 | 03 | 2018-12-28 | 2019-02-01 | Rucaparib | 01 | N | CAPECITABINE + TEMOZOLOMIDE | 101633964 |
| 160015745 | 160013078 | 1.72 | 99.7 | Palliative (P) | 2019-05-19 | 2019-05-19 | EURO-EWING | 02 | N | IFOSFAMIDE | 100977969 |
| 160015746 | 160013079 | 1.68 | 75.1 | Palliative (P) | 2022-01-10 | 2022-01-20 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | N | NB HRNBL-1 ISOTRETINOIN | 101622762 |
| 160015747 | 160013080 | 1.65 | 55.5 | Palliative (P) | 2016-10-03 | 2017-04-02 | Etoposide oral | 02 | N | ATEZOLIZUMAB | 100561282 |
| 160015749 | 160013081 | 1.63 | 57.5 | Neo-adjuvant (N) | null | 2019-12-29 | LANREOTIDE | N | N | IFOSFAMIDE | 101212494 |
| 160015750 | 160013082 | 1.77 | 87 | Palliative (P) | 2017-11-16 | 2018-05-29 | Ifosfamide | 02 | N | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 101263802 |
| 160015751 | 160013083 | 1.64 | 42.5 | Palliative (P) | 2019-06-03 | 2019-06-11 | null | 02 | N | NOT MATCHED | 100714421 |
| 160015752 | 160013084 | 1.72 | 67.9 | Curative (C) | 2019-09-19 | 2019-09-30 | STS Rhabdo RMS 2005 Vin Cyclo | 01 | N | OLARATUMAB | 101544954 |
| 160015755 | 160013085 | null | 54.8 | Curative (C) | 2018-06-18 | 2018-06-29 | BUSULFAN + MELPHALAN | 02 | N | GEMCITABINE | 100305949 |
| 160015757 | 160013086 | 1.66 | 16.6 | null | 2019-08-09 | 2019-08-09 | NB HRNBL-1 Isotretinoin | 02 | null | CAPECITABINE + OXALIPLATIN | 100425329 |
| 160015758 | 160013087 | 1.65 | 53.2 | Curative (C) | 2018-09-15 | 2018-09-30 | EW EuroEwing 2012 Arm B IE | 02 | N | IRINOTECAN + TEMOZOLOMIDE | 101541692 |
| 160015761 | 160013088 | 0 | 77 | Palliative (P) | 2019-03-28 | 2020-03-18 | GEMCITABINE | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100995533 |
| 160015766 | 160013089 | null | 64 | Neo-adjuvant (N) | 2019-05-06 | 2019-05-15 | Doxorubicin + Ifosfamide | 02 | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 100518805 |
| 160015769 | 160013090 | 0 | 39.2 | null | 2018-01-12 | 2018-02-16 | Bortezomib +/- Dexamethasone | 02 | null | OLARATUMAB | 101344878 |
| 160015771 | 160013091 | 0 | 7.7 | Adjuvant (A) | 2021-11-04 | 2021-12-02 | Carboplatin + Etoposide iv&po | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101650294 |
| 160015772 | 160013092 | 1.67 | 75 | null | 2016-11-29 | 2016-11-29 | PEMBROLIZUMAB | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100283352 |
| 160015773 | 160013093 | null | null | Palliative (P) | 2019-03-23 | 2019-05-18 | ETOP 13-18 BEAT-meso Trial | 02 | N | PROMISE-MESO TRIAL | 101161304 |
| 160015774 | 160013094 | 1.79 | 10.5 | Curative (C) | 2021-01-23 | 2021-02-09 | STS Rhabdomyosarco RMS 2005 IVADoVV | 02 | N | EW REL REECUR IRINOTECAN/TEMOZOLOMIDE | 100906307 |
| 160015775 | 160013095 | 0 | 94 | Palliative (P) | 2019-12-05 | 2019-12-16 | Doxorubicin + Ifosfamide | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 101406357 |
| 160015776 | 160013096 | 1.59 | 102 | Curative (C) | 2019-10-12 | 2019-10-27 | Pazopanib | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100072120 |
| 160015781 | 160013097 | 1.72 | 87.05 | Curative (C) | 2019-09-24 | 2019-11-20 | FLUOROURACIL + IRINOTECAN | 02 | N | PEMBROLIZUMAB | 101746497 |
| 160015782 | 160013098 | 1.7 | 70 | null | 2018-07-18 | 2019-07-15 | ETOPOSIDE | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100247291 |
| 160015786 | 160013099 | null | null | Palliative (P) | 2019-11-07 | 2019-11-16 | Ifosfamide | 02 | N | ICON8B TRIAL | 101725765 |
| 160015789 | 160013100 | 1.56 | 71.1 | Curative (C) | null | 2017-02-22 | Doxorubicin + Ifosfamide | 2 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 100124778 |
| 160015791 | 160013101 | 1.75 | 80.8 | Adjuvant (A) | 2017-12-04 | 2017-12-06 | Ifosfamide PVI 1g/m2 14day | 02 | N | STS RHABDO RMS 2005 VIN CYCLO | 101717290 |
| 160015793 | 160013102 | 1.82 | 79 | null | 2018-05-29 | 2018-06-04 | NB HRNBL-1 BUMEL MAT | 02 | null | OLAPARIB | 101401613 |
| 160015794 | 160013103 | null | 77.2 | null | 2019-01-06 | 2019-03-16 | Ifosfamide | 02 | null | CYCLOPHOSPHAMIDE | 100547941 |
| 160015799 | 160013104 | 1.56 | null | Palliative (P) | null | 2016-11-08 | Ifosfamide | 02 | N | PEMBROLIZUMAB | 100988419 |